Latest news with #cancerdiagnostics
Reuters
14 hours ago
- Business
- Reuters
Sixth Street-backed Caris Life Sciences targets $5.3 billion valuation in US IPO
June 9 (Reuters) - Cancer diagnostic firm Caris Life Sciences said on Monday it is targeting a valuation of up to $5.35 billion in its initial public offering in the United States. Irving, Texas-based Caris plans to raise up to $424 million by offering 23.5 million shares priced between $16 and $18 apiece. The IPO market is heating up as high-profile companies move ahead with their stock market listings in a calmer period after tariff-related volatility stifled deal activity earlier this year. In 2021, Caris raised $830 million at a $7.83 billion valuation in a funding round led by investment firm Sixth Street. Caris will trade on the Nasdaq under the symbol "CAI." BofA Securities, J.P. Morgan, Goldman Sachs, and Citigroup are the lead underwriters for the offering.
Washington Post
12-05-2025
- Business
- Washington Post
OncoCyte: Q1 Earnings Snapshot
IRVINE, Calif. — IRVINE, Calif. — OncoCyte Corp. (OCX) on Monday reported a loss of $6.7 million in its first quarter. The Irvine, California-based company said it had a loss of 26 cents per share. The cancer diagnostic test developer posted revenue of $2.1 million in the period. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on OCX at
Associated Press
06-05-2025
- Business
- Associated Press
Volta Labs, Inc. and Hartwig Medical Foundation Collaborate to Advance Oncological Discoveries with the Callisto™ Sample Prep System
BOSTON and AMSTERDAM, May 6, 2025 /PRNewswire/ -- Volta Labs, Inc. , a leading genomics applications company, and Hartwig Medical Foundation , a global pioneer in genomics-driven oncology research and clinical care, today announced a multi-year collaboration aimed at developing a sample processing platform for the most common cancer diagnostic sequencing applications. This will involve advancement of the next generation of sample prep 'apps' spanning whole genome sequencing, targeted sequencing, ctDNA, and RNA profiling across multiple sequencing technologies. Volta has successfully launched the Hybrid Capture for IDT xGen™, v2 Chemistry, app as the first major milestone in their collaboration. Together, the teams leveraged Callisto's unique technology — including uniform temperature control and full automation of hybrid capture — to deliver a truly end-to-end, closed-system solution. Hybrid capture, a commonly used sequencing preparation, has been particularly challenging for other automation platforms. This Volta app is fully compatible with Hartwig's clinically validated OncoAct panel, used for its comprehensive cancer mutation profiling. 'At Hartwig Medical Foundation, we are focused on delivering the most complete cancer diagnostic tests, including the use of cheap and fast whole genome and transcriptome sequencing. The oncology testing landscape is evolving rapidly with the need for testing more and more complex biomarkers and the simultaneous rise of new sequencing technologies,' said Edwin Cuppen, Director of Hartwig Medical Foundation. 'We need a system that consistently delivers high-quality data to power data-driven improvements in healthcare. To achieve this, we need versatile sample preparation technologies that can evolve alongside us and that can run in any test laboratory.' Following the successful adoption of Callisto at Hartwig, Volta and Hartwig have agreed to expand their partnership to further develop workflows that leverage the innovative capabilities of the Callisto platform. The teams are currently developing library preparation for tissue- and ctDNA-based whole genome sequencing to diagnose tumors and monitoring disease burden. 'We began collaborating with the Volta Labs team two years ago, and we believe the Callisto Sample Prep System represents the future of sample preparation in diagnostic labs. Callisto already delivers an excellent hybrid capture workflow, and we are now working together to enable whole genome sequencing on various DNA sources as well as new capabilities across multiple emerging short-read sequencing platforms. Once development is complete, we plan to integrate the Callisto platform into clinical studies and adopt it for routine use in our clinical accredited testing workflows,' said Ewart de Bruijn, Innovation Lead at Hartwig Medical Foundation. 'Hartwig's partnership and adoption of Callisto mark a major milestone in our mission to make complex molecular workflows simple, accessible, and scalable,' said Udayan Umapathi, Founder and CEO of Volta Labs. 'And this is just the beginning. Together, we're rethinking the entire oncology pipeline — starting with the most robust and uniform hybrid capture workflow on the market, to complement our other apps on DNA long and short extraction, Illumina compatible library prep, and PacBio library prep. We're now focused on next-generation applications, including high-sensitivity ctDNA library prep and new oncology workflows for emerging sequencing platforms.' About Hartwig Hartwig Medical Foundation is a global leader in genomics-driven oncology research and clinical care. They improve cancer patient care by generating, analyzing, and sharing high-quality genomic and clinical data, enhancing diagnostics, enabling personalized treatments, and supporting the development of more effective future therapies. About Volta Labs Volta Labs is a genomics applications company that has developed a cutting-edge digital fluidics platform to maximize performance and scalability of sample preparation in genomics while providing unparalleled consistency. Volta is transforming the way biological research and analyses are performed, allowing scientists to focus on what they do best -- pushing the boundaries of biology. Media contact: Abdul Mohammed [email protected] View original content to download multimedia: SOURCE Volta Labs Inc.
